Emerging treatments
Odronextamab
One phase 2, open-label, multicentre study of odronextamab (an anti-CD20/-CD3 bispecific antibody) reported a complete response rate of 73.4% (at 20.1 months efficacy follow-up) among patients with relapsed/refractory follicular lymphoma (FL).[193] In another phase 2 study, the complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) was 31.5% at 29.9-month efficacy follow-up.[194] Odronextamab is approved in Europe for adults with relapsed/refractory FL or DLBCL after two or more lines of systemic therapy. Odronextamab is not approved in the US (approval was denied).
Blinatumomab
Blinatumomab (an anti-CD19/-CD3 bispecific antibody approved by the US Food and Drug Administration [FDA] in the setting of B-cell precursor acute lymphoblastic leukaemia) has shown promise as salvage therapy and consolidation therapy in relapsed/refractory NHL.[195][196][197][198][199][200]
Tucidinostat
An orally active benzamide-type histone deacetylase inhibitor (also known as chidamide). Investigated as a constituent agent of conditioning therapy for high-risk or relapsed/refractory NHL.[201] Clinical trials involving tucidinostat in patients with relapsed/refractory NHL are ongoing.[202]
Use of this content is subject to our disclaimer